Phase I trial of intratumoral PVSRIPO in patients with unresectable, treatment-refractory melanoma

BACKGROUND: While programmed cell death protein 1 (PD-1) and programmed death-ligand 1 (PD-L1) antagonists have improved the prognosis for many patients with melanoma, around 60% fail therapy. PVSRIPO is a non-neurovirulent rhinovirus:poliovirus chimera that facilitates an antitumor immune response...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:J Immunother Cancer
Prif Awduron: Beasley, Georgia M, Nair, Smita K, Farrow, Norma E, Landa, Karenia, Selim, Maria Angelica, Wiggs, Carol Ann, Jung, Sin-Ho, Bigner, Darell D, True Kelly, Andrea, Gromeier, Matthias, Salama, April KS
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: BMJ Publishing Group 2021
Pynciau:
Oncolytic and Local Immunotherapy
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC8057552/
https://ncbi.nlm.nih.gov/pubmed/33875611
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jitc-2020-002203
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg